Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif

Journal of Virology

Volumn 75, Issue 3, 2001, Pages 1301-1311

  Altfeld, M A ^a   Livingston, B ^a   Reshamwala, N ^a   Nguyen, P T ^a   Addo, M M ^a   Shea, A ^a   Newman, M ^a   Fikes, J ^a   Sidney, J ^a   Wentworth, P ^a   Chesnut, R ^a   Eldridge, R L ^a   Rosenberg, E S ^a   Robbins, G K ^a   Brander, C ^a   Sax, P E ^a   Boswell, S ^a   Flynn, T ^a   Buchbinder, S ^a   Goulder, P J R ^a   Walker, B D ^a   Sette, A ^a   Kalams, S A ^a   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A2 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PEPTIDE; PROTEIN;

ALLELE; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; PREDICTION; PRIORITY JOURNAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; BINDING SITES; CELL LINE; EPITOPES, T-LYMPHOCYTE; GENE PRODUCTS, VPR; HIV-1; HLA-A2 ANTIGEN; HUMANS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0035152281     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.3.1301-1311.2001     Document Type: Article

References (86)

1. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia
2. The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1
3. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection
4. Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: Rapid characterization of CTL responses by enzyme-linked immunospot assay
5. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
6. Restoration of the immune system with anti-retroviral therapy
7. Nomenclature for factors of the HLA system, 1998
8. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus
9. Lack of strong immune selection pressure by the immunodominant HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection
10. T lymphocyte responses in HIV-1 infection: Implications for vaccine development
11. Viral protein R of HIV-1
12. Comprehensive, serologically equivalent DNA typing for HLA-B by PCR using sequence-specific primers (PCR-SSP)
13. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients
14. Survival after introduction of HAART in people with known duration of HIV-1 infection
15. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients
16. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection
17. An HLA-B35-restricted epitope modified at an anchor residue results in an antagonist peptide
18. Changes in thymic function with age and during the treatment of HIV infection
19. Characterization of HLA-A 0201-restricted cytotoxic T cell epitopes in conserved regions of the HIV type 1 gp160 protein
20. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef
21. Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated HIV-infected patients
22. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
23. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides
24. Control of acute infection with lymphocytic choriomeningitis virus in mice that cannot present an immunodominant viral cytotoxic T lymphocyte epitope
25. Identification of a novel human leukocyte antigen A26-restricted epitope in a conserved region of Gag
26. Identification of a novel HLA-A24-restricted cytotoxic T-lymphocyte epitope within HIV-1 Nef
27. Identification of a novel HLA-B*3501-restricted cytotoxic T lymphocyte epitope using overlapping peptides
28. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS
29. Combined structural and immunological refinement of HIV-1 HLA-B8-restricted cytotoxic T lymphocyte epitopes
30. Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA) - Identical siblings with HLA-A*0201 are influenced by epitope mutation
31. The great escape - AIDS viruses and immune control
32. Anti-HIV cellular immunity: Recent advances towards vaccine design
33. Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children
34. Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART)
35. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens
36. Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor
37. HIV-1-specific cytotoxic T lymphocyte response in healthy, long-term nonprogressing seropositive persons
38. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load
39. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection
40. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes
41. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques
42. Identification of subdominant cytotoxic T lymphocyte epitopes encoded by autologous HIV type 1 sequences, using dendritic cell stimulation and computer-driven algorithm
43. HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells
44. Acute human immunodeficiency virus type 1 infection
45. Levels of human immunodeficienicy virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy
46. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy
47. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics
48. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression
49. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
50. Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection
51. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides
52. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
53. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy
54. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation
55. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
56. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: Results from the Euro-SIDA study
57. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort
58. HIV-1-specific CD4+ T cells are detectable in most individuals with active H1V-1 infection, but decline with prolonged viral suppression
59. Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease
60. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy
61. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection
62. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors
63. Failure of double protease inhibitor therapy as a salvage therapy for HIV-infected patients resistant to conventional triple therapy
64. Immune control of HIV-1 after early treatment of acute infection
65. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women
66. Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly exposed persistently seronegative donors
67. Immune responses in HIV exposed seronegatives: Have they repelled the virus?
68. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant
69. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules
70. Clinical efficacy of protease inhibitor based antiretroviral combination therapy - A prospective cohort study
71. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
72. HLA supertypes and supermotifs: A functional perspective on HLA polymorphism
73. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes
74. Immune reconstitution in HAART-treated children with AIDS
75. Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs
76. Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules
77. Measurement of MHC/peptide interactions by gel filtration
78. Uncovering subdominant cytotoxic T-lymphocyte responses in lymphocytic choriomeningitis virus-infected BALB/c mice
79. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex
80. HIV-specific cytotoxic T lymphocytes in seropositive individuals
81. Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1
82. HAART in HIV-infected patients: Restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia
83. Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome
84. Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphoeytes
85. CD8+ cells in human immunodeficiency virus type I pathogenesis: Cytolytic and noncytolytic inhibition of viral replication